|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,890,000 |
Market
Cap: |
N/A |
Last
Volume: |
2,615,875 |
Avg
Vol: |
1,187,095 |
52
Week Range: |
$7.07 - $7.07 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cundy Kenneth C |
SVP, Preclinical Development |
|
2010-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
625 |
15,130 |
|
- |
|
Savello David R |
SVP, Development |
|
2010-02-01 |
4 |
D |
$18.50 |
$3,978 |
D/D |
(215) |
21,267 |
|
- |
|
Savello David R |
SVP, Development |
|
2010-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
500 |
21,482 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2010-01-28 |
4 |
D |
$18.55 |
$7,977 |
D/D |
(430) |
34,248 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2010-01-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,000 |
34,678 |
|
- |
|
Gallop Mark A |
SVP, Research |
|
2010-01-28 |
4 |
D |
$18.55 |
$5,973 |
D/D |
(322) |
19,447 |
|
- |
|
Gallop Mark A |
SVP, Research |
|
2010-01-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
750 |
19,769 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2010-01-28 |
4 |
D |
$18.55 |
$9,980 |
D/D |
(538) |
14,505 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2010-01-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
15,043 |
|
- |
|
Savello David R |
SVP, Development |
|
2010-01-28 |
4 |
D |
$18.55 |
$6,975 |
D/D |
(376) |
20,982 |
|
- |
|
Savello David R |
SVP, Development |
|
2010-01-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
875 |
21,358 |
|
- |
|
Stamler David A |
SVP, Chief Medical Officer |
|
2010-01-28 |
4 |
D |
$18.55 |
$7,977 |
D/D |
(430) |
5,793 |
|
- |
|
Stamler David A |
SVP, Chief Medical Officer |
|
2010-01-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,000 |
6,223 |
|
- |
|
Angotti Vincent |
SVP & CCO |
|
2010-01-28 |
4 |
D |
$18.55 |
$7,977 |
D/D |
(430) |
4,776 |
|
- |
|
Angotti Vincent |
SVP & CCO |
|
2010-01-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,000 |
5,206 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2010-01-04 |
4 |
AS |
$18.75 |
$38,357 |
D/D |
(2,000) |
13,793 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2010-01-04 |
4 |
OE |
$1.50 |
$3,000 |
D/D |
2,000 |
15,793 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2009-10-06 |
4 |
AS |
$22.00 |
$22,000 |
D/D |
(1,000) |
13,792 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2009-10-06 |
4 |
OE |
$1.80 |
$1,800 |
D/D |
1,000 |
14,792 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2009-09-17 |
4 |
AS |
$24.15 |
$24,631 |
D/D |
(1,000) |
13,792 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2009-09-17 |
4 |
OE |
$1.80 |
$1,800 |
D/D |
1,000 |
14,792 |
|
- |
|
Angotti Vincent |
SVP & CCO |
|
2009-08-10 |
4 |
D |
$20.10 |
$17,949 |
D/D |
(893) |
4,107 |
|
- |
|
Angotti Vincent |
SVP & CCO |
|
2009-08-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
5,000 |
|
- |
|
Stamler David A |
SVP, Chief Medical Officer |
|
2009-08-10 |
4 |
D |
$20.10 |
$17,949 |
D/D |
(893) |
4,723 |
|
- |
|
Stamler David A |
SVP, Chief Medical Officer |
|
2009-08-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
5,616 |
|
- |
|
663 Records found
|
|
Page 14 of 27 |
|
|